Why the study?
Fluid therapy is essential in acute brain injured patients to maintain physiology and avoid complications, but diverse pathways of secondary injury and systemic deterioration challenge fluid management.
In acute brain injured patients, fluid therapy should target euvolemia and be managed carefully, as intravenous fluids act as drugs with potential for both benefit and harm.
Euvolemia remains the fluid target in ABI to minimize complications; expert opinion leaves optimal monitoring and fluid selection open for prospective trials.
Adequate fluid therapy in the acute brain injured (ABI) patient is essential for maintaining an adequate brain and systemic physiology and preventing intra- and extracranial complications. The target of euvolemia, implying avoidance of both hypovolemia and fluid overloading (or "hypervolemia," by definition associated with fluid extravasation leading to tissue edema) is of key importance. Primary brain injury can be aggravated by secondary brain injury and systemic deterioration through diverse pathways which can challenge appropriate fluid management, e.g. neuroendocrine and electrolyte disorders, stress cardiomyopathy (also known as cardiac stunning) and neurogenic pulmonary edema. This is an updated expert opinion aiming to provide a practical overview on fluid therapy in the ABI patient, partly based on more recent work and stressing the fact that intravenous fluids should be regarded as drugs, with their inherent potential for both benefit and (unintended) harm.
No takes yet. Share an insight, caveat, or question.
Ergezen et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: